STOCK TITAN

Beam Therapeutics Inc. - BEAM STOCK NEWS

Welcome to our dedicated news page for Beam Therapeutics (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beam Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beam Therapeutics 's position in the market.

Rhea-AI Summary
Beam Therapeutics Inc. reported new preclinical data on its in vivo drug candidate, BEAM-301, which demonstrated the ability to correct the R83C mutation of glycogen storage disease type Ia (GSDIa). The data showed that a single dose of BEAM-301 resulted in long-term survival, sustained editing of G6PC in the liver, normalization of glucose homeostasis and metabolites, and prevention of hypoglycemia. Beam plans to submit a U.S. IND application in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
-
Rhea-AI Summary
Beam Therapeutics announces portfolio priorities and plans to streamline business operations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
none
-
Rhea-AI Summary
Beam Therapeutics reports positive preclinical data for BEAM-302, demonstrating its ability to correct the PiZ mutation associated with severe alpha-1 antitrypsin deficiency (AATD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
Rhea-AI Summary
Beam Therapeutics Inc. announces the first patient treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell therapy candidate for T-cell cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Beam Therapeutics Inc. to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
-
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) reports Q2 2023 financial results and clinical progress. The company is well-capitalized with $1.1B in cash. BEACON trial for BEAM-101 in Sickle Cell Disease is progressing with consented patients. First patient consented in Phase 1/2 trial of BEAM-201 in T-ALL/T-LL. BEAM-302 development accelerated, with regulatory filing expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) will participate in fireside chats at two investor conferences in May.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
Beam Therapeutics Inc.

Nasdaq:BEAM

BEAM Rankings

BEAM Stock Data

1.75B
73.33M
1.84%
89.58%
16.47%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About BEAM

beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team:  a community of fearless innovators  rigorous and honest in our research  listening with open minds  committed to each other